Study Links Calcium-Channel Blockers to Higher Kidney Risk in Type 2 Diabetes
A recent study has revealed that dihydropyridine calcium-channel blockers (DCCBs), commonly prescribed to lower blood pressure, are linked to a 33% increased risk of major adverse kidney events in individuals with Type 2 diabetes. The findings, presented on August 18, 2026, are based on an analysis of health records from 31,031 adults diagnosed with Type 2 diabetes. DCCBs are often used as second-line treatments for patients suffering from diabetic kidney disease (DKD), a condition that can lead to kidney failure due to prolonged high blood sugar levels damaging the small blood vessels in the kidneys.
The study compared patients taking DCCBs with those receiving alternative antihypertensive medications over a median follow-up period of approximately 3.5 years. It was noted that diabetic kidney disease is one of the leading causes of kidney failure globally, making the management of blood pressure crucial as hypertension can accelerate renal decline.
The findings suggest that DCCBs may alter blood flow dynamics in the kidneys, potentially exacerbating existing conditions in patients with DKD. Specifically, DCCBs may relax the blood vessels supplying blood to the kidney's filtering units more than those carrying blood away, leading to increased pressure within these structures and further kidney damage. This imbalance could explain the observed higher risk of kidney events.
Lead author Dr. Timna Agur emphasized the importance of these findings, stating that the kidney-protective effects of other medications, such as renin-angiotensin system (RAS) inhibitors and sodium-glucose cotransporter-2 (SGLT2) inhibitors, may not be sufficient to counterbalance the risks associated with DCCBs. The study's observational nature means it cannot definitively establish causation, but the association warrants further investigation.
Dr. Agur concluded that more prospective studies and randomized controlled trials are necessary to clarify the safest blood pressure management strategies for patients with DKD. Given the widespread prescription of DCCBs, even a slight increase in kidney risk could have significant implications for many patients. The study highlights the ongoing need for careful evaluation of treatment options in managing diabetes and its complications, particularly concerning kidney health.




